Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T therapy shows promise for Hard-to-Treat myeloma, but trial ends early

NCT ID NCT05172596

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a new CAR-T cell therapy called PHE885 in adults with relapsed and refractory multiple myeloma. The therapy targets a protein called BCMA on myeloma cells. The trial aimed to see how many patients responded, but it was terminated early. Results may still help researchers understand if this approach works for people who have run out of other options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PHE885 (a type of CAR-T cell therapy that targets BCMA on myeloma cells)
What this could lead to
If successful, this could point toward a new treatment option for people with multiple myeloma that has not responded to other therapies.
What could go wrong
This trial was terminated early, so results are limited. CAR-T therapies can cause serious side effects like cytokine release syndrome and nerve problems. It is unclear if PHE885 will be effective or safe enough for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Emory University School of Medicine-Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Fred Hutch Cancer Research

    Seattle, Washington, 98109, United States

  • Novartis Investigative Site

    Camperdown, New South Wales, 2050, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    Salvador, Estado de Bahia, 41253-190, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 01509-900, Brazil

  • Novartis Investigative Site

    Calgary, Alberta, T2N 5G2, Canada

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Poitiers, 86021, France

  • Novartis Investigative Site

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    Heidelberg, 69120, Germany

  • Novartis Investigative Site

    Athens, 106 76, Greece

  • Novartis Investigative Site

    Thessaloniki, 570 10, Greece

  • Novartis Investigative Site

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4678602, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 060 8648, Japan

  • Novartis Investigative Site

    Kyoto, Kyoto, 602-8566, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 980 8574, Japan

  • Novartis Investigative Site

    Riyadh, 11211, Saudi Arabia

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    Salamanca, 37007, Spain

  • Novartis Investigative Site

    Glasgow, Scotland, G51 4TF, United Kingdom

  • Novartis Investigative Site

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Oregon Health Sciences University

    Portland, Oregon, 97239, United States

  • Stanford University

    Palo Alto, California, 94304, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.